Drug
Arm1
Arm1 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
3
100%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Other(1)
Detailed Status
Not yet recruiting1
unknown1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
not_yet_recruiting133%
unknown133%
completed133%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingphase_2
Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer
NCT07714447
completedphase_2
A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates
NCT06398808
unknownphase_2
Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study
NCT02748707
Clinical Trials (3)
Showing 3 of 3 trials
NCT07714447Phase 2
Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer
NCT06398808Phase 2
A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates
NCT02748707Phase 2
Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3